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Lipopolysaccharide (LPS) triggers deleterious systemic inﬂammatory responses when released
into the circulation. LPS-binding protein (LBP) in the serum plays an important role in modi-
fying LPS toxicity by facilitating its interaction with LPS signaling receptors, which are
expressed on the surface of LPS-responsive cells. We have previously demonstrated that high
mobility group box 1 (HMGB1) can bind to and transfer LPS, consequently increasing LPS-
induced TNF-a production in human peripheral blood mononuclear cells (PBMCs). We report
here on the identiﬁcation of two LPS-binding domains within HMGB1. Furthermore, using 12
synthetic HMGB1 peptides, we deﬁne the LPS-binding regions within each domain. Among
them, synthetic peptides HPep1 and HPep6, which are located in the A and B box domains of
HMGB1, bind to the polysaccharide and lipid A moieties of LPS respectively. Both HPep1 and
HPep6 peptides inhibited binding of LPS to LBP and HMGB1, LBP-mediated LPS transfer to
CD14, and cellular uptake of LPS in RAW264.7 cells. These peptides also inhibited LPS-induced
TNF-a release in human PBMCs and induced lower levels of TNF-a in the serum in a sub-
clinical endotoxemia mouse model. These results indicate that HMGB1 has two LPS-binding
peptide regions that can be utilized to design anti-sepsis or LPS-neutralizing therapeutics.
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Introduction
Lipopolysaccharide (LPS) is the main cause of Gram-negative
bacterial sepsis. LPS consists of a lipid A component, a sugar
moiety that forms the core, and an O-polysaccharide of variable
length [1]. When LPS is introduced into the bloodstream, LPS-
binding protein (LBP) recognizes the LPS molecules and catalyzes
the movement of LPS from LPS aggregates. LBP transfers LPS to
CD14, which in turn transfers LPS to the TLR4-MD2 receptor.
Recently, the crystal structure of the TLR4-MD2-LPS complex has
been determined [2]. Although there are several proteins that
bind LPS, LBP is the ﬁrst key protein that initiates and ampliﬁes
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septic shock syndrome.
The nuclear protein high-mobility group box 1 protein
(HMGB1) is involved in nucleosome stabilization, gene transcrip-
tion, and neurite outgrowth [3]. HMGB1 can be actively or
passively released into the extracellular space through acetylation
[4], phosphorylation [5, 6], methylation [7], or cell necrosis [8].
HMGB1 can trigger inﬂammation [8] and is a late mediator of
endotoxemia and sepsis in both animal models and humans [9–12].
Although HMGB1 is a well-known mediator of endotoxemia and a
proinﬂammatory cytokine-like protein in vivo, puriﬁed recombi-
nant HMGB1 only has weak in vitro proinﬂammatory activity, such
as the induction of TNF-a production [13, 14]. HMGB1 can form
highly inﬂammatory complexes with CpG DNA [15, 16] and IL-1b
[17], suggesting that HMGB1 is necessary but not sufﬁcient to
induce inﬂammation [18]. Previously, we proposed that HMGB1
can interact with LPS and transfer LPS to CD14 to enhance LPS-
mediated inﬂammation [14]; HMGB1 may transfer LPS to CD14
under the conditions where LBP is absent, such as in LBP-deﬁcient
mice [19], or where and when the level of HMGB1 is highly
increased such as in Gram-negative bacterial infections [9].
In this study, we describe two HMGB1 synthetic peptides (of
12 tested) that can bind to LPS, namely HPep1 (HMGB1
3–15) and
HPep6 (HMGB1
80–96); these peptides bind to the polysaccharide
and lipid A moieties of LPS respectively. We demonstrate that
both these LPS-binding peptides inhibit LPS binding to LBP, LBP-
mediated LPS transfer to CD14, and cellular uptake of LPS in
RAW264.7 cells. Both HPep1 and HPep6 inhibited LPS-induced
TNF-a release in human peripheral blood mononuclear cells
(PBMCs) and also decreased serum levels of TNF-a in a mouse
model of subclinical endotoxemia, suggesting that these two LPS-
binding peptides may have potential as antiseptic therapeutics.
Results
HMGB1 A and B box proteins bind to different moieties
of LPS
We previously found that HMGB1 can bind to LPS and transfer it to
CD14 thereby enhancing LPS-mediated inﬂammation, demonstrat-
ing that HMGB1 plays a role in LPS-mediated TNF-a production
[14]. In the current study, we further investigated the interaction
between HMGB1 and LPS, and evaluated whether LPS-binding
HMGB1 peptides can neutralize LPS. We ﬁrst evaluated whether the
A and B box domains of HMGB1 play a role in LPS binding. For this,
6-His-tagged HMGB1 A and B box proteins were produced in
Escherichia coli [ 5 ]a n di n c u b a t e dw i t hb i o t i n - t a g g e dL P Sf o r
precipitation with streptavidin beads. The protein containing the
HMGB1 B box domain bound very strongly to LPS, whereas the
protein containing the A box domain bound weakly to LPS (Fig. 1A).
We next investigated which moiety of LPS – the poly-
saccharide or lipid A moiety – binds to the A and B box proteins
of HMGB1. Biotin–LPS was incubated with a constant amount of
HMGB1 A box protein in the presence of various amounts of
partially delipidated LPS and lipid A as competitors, and the
binding of A box protein to biotin–LPS was examined by Western
blotting. The binding of the A box protein to biotin–LPS was
inhibited by delipidated LPS although not completely inhibited
due to its partial delipidation; however, lipid A did not inhibit the
binding of the A box protein to LPS (Fig. 1B).
We next investigated the binding of the HMGB1 B box domain
to LPS. When delipidated LPS and lipid A were added to the
mixture of biotin–LPS and the HMGB1 B box protein, the binding
of HMGB1 B box to biotin–LPS was inhibited by lipid A in a dose
dependent manner, but not by delipidated LPS (Fig. 1C, upper).
This inhibition was also observed using Re595 LPS and unlabeled
WT LPS, both of which contain the lipid A moiety of LPS (Fig. 1C,
lower). To predict the binding mode of HMGB1 and lipid A, we
generated a model of HMBG1 and lipid A complex structure using
molecular docking. The head region of lipid A is surrounded by the
positive surface of HMGB1 box B (Supporting Information Fig. 1).
Among four phosphate groups in the lipid A head and inner core
regions of LPS, three bind to basic patches of HMBG1. The fatty
acid tails of lipid A are forward to HMGB1 box A, forming weak
hydrophobic interactions with nearby hydrophobic residues and
suggesting that a major contribution of lipid A binding to HMGB1
is caused by the B box domain rather than by the A box.
These data demonstrate that the HMGB1 B box protein binds
to the lipid A moiety of LPS. These results suggest that HMGB1 A
and B box proteins bind to two different moieties of LPS, namely
the delipidated polysaccharide and lipid A moieties respectively.
These data are consistent with our previous data obtained using
surface plasmon resonance analyses [14].
Mapping of the LPS binding region of HMGB1
To further investigate the binding of A and B box HMGB1
proteins to LPS, 12 biotin-labeled HMGB1 peptides were
synthesized (Fig. 2A) and their LPS-binding properties analyzed.
Given that both the LPS and the heparin-binding region have the
motif BBXB, where B is any basic aa and X is any hydrophobic aa
[20], the length of the peptides was constrained to preserve this
motif. Each biotin-labeled peptide was incubated with LPS and
precipitated with streptavidin beads. As shown in Fig. 2B (left
and right panel), HMGB1 peptides No. 1 (HPep1, HMGB1
3–15)
and No. 6 (HPep6, HMGB1
80–96) bound to LPS in contrast to the
other ten peptides. We used an ELISA assay to conﬁrm binding of
only these two peptides to LPS. The biotin-labeled peptides were
added to LPS-coated wells and HRP-conjugated streptavidin was
added, and only HPep1 and HPep6 bound to LPS-coated wells in
a dose-dependent manner (Fig. 2C).
HPep1 and HPep6 bind to different moieties of LPS and
inhibit binding of LPS to LBP and HMGB1
We next investigated whether HPep1 and HPep6 bind the
polysaccharide and lipid A moieties of LPS respectively, because
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HPep6 contains a B box HMGB1 protein sequence and a part of
the linker region, respectively (Fig. 2A). A constant amount of
biotin–HPep1 or biotin–HPep6 was added to LPS-coated wells in
the presence of various concentrations of delipidated LPS,
lipid A, or Re595 LPS as competitors, and the binding of each
biotin–peptide to LPS-coated wells was probed with HRP-
conjugated streptavidin. WT LPS was used as a positive control
competitor. As shown in Fig. 3A, the binding of HPep1 to LPS was
dose dependently inhibited by polysaccharide moiety-containing
partially delipidated LPS and WT LPS. On the contrary, the
binding of HPep6 to LPS was inhibited by lipid A-containing LPS,
Re595 LPS, and WT LPS. Re595 LPS and lipid A showed no
inhibition to HPep1 to LPS at the concentration of 20mg/mL, and
delipidated LPS also showed no inhibition of HPep6 to LPS. These
results demonstrate that HPep1 and HPep6 bind to the
polysaccharide and lipid A moieties of LPS respectively.
We next investigated whether HPep1 and HPep6 could inhibit
the binding of LPS to LBP. For this, a constant amount of LBP was
added to LPS-coated wells in the presence of various concentra-
tions of HPep1 and HPep6. LPS binding to LBP (Fig. 3B) and
HMGB1 (Fig. 3C) was dose dependently inhibited by HPep1 and
Figure 1. LPS-binding speciﬁcity of HMGB1 domains. (A) Biotin-labeled E. coli LPS was incubated with 6 His-tagged HMGB1 A and B box proteins
and pull-down assays were performed. The beads were subjected to 12% SDS-PAGE and Western blot analysis was performed using anti-His Ab.
(B, C) An aliquot of 5mg/mL of biotin–LPS was incubated with 5mg/mL of His-tagged A box or B box HMGB1 protein that had been preincubated with
various amounts of E. coli delipidated LPS, S. minnesota lipid A, S. minnesota Re595 LPS, or WT S. minnesota LPS as inhibitors. Biotin–LPS was
precipitated and analyzed using Western blotting with an anti-His Ab. (C) The line indicates the cutline of the same blot membrane. Data shown
are representative of two independent experiments.
Figure 2. Mapping of the LPS-binding regions of HMGB1. (A) Twelve synthetic biotin-labeled HMGB1 peptides were prepared for the LPS binding
study. Boxes A and B and the acidic tail domain are underlined. (B) Brieﬂy, 10mg/mL of each biotin-labeled HMGB1 peptide was incubated with
10mg/mL of LPS. Pull-down assays were performed with streptavidin agarose beads and analyzed by Western blotting. The membrane was probed
with an anti-LPS Ab. WT HMGB1 was used as a positive control (left). This assay was repeated using four selected peptides (right). (C) Microtiter
plates were coated with 10mg/mL of LPS in PBS and washed with 0.05% Tween-20 PBS. Various concentrations of each biotin-labeled HMGB1
peptide were added to the wells followed by the addition of HRP-conjugated streptavidin. TMB solution was used as a substrate for color
development. Data shown are representative of two independent experiments.
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the positive control inhibitor, polymyxin B.
The HMGB1 B box protein catalyzes the movement of
LPS from micelles to CD14
We next investigated which domain of HMGB1 catalyzes the
ﬂuorescence transition from an aggregated LPS state using
BODIPY FL-LPS. BODIPY FL-LPS was incubated with soluble (s)
CD14 in the presence of various concentrations of HMGB1 A and
B box proteins, and the changes in ﬂuorescence were measured.
When BODIPY FL-LPS was incubated with WT HMGB1 in the
presence of sCD14, the ﬂuorescence level was 1.120, which is
similar to that of BODIPY FL-LPS incubated with LBP (Fig. 4A)
[14]. When HMGB1 A and B box proteins were tested, the level of
ﬂuorescence of BODIPY FL-LPS was dose dependently increased
by the B box protein, but no detectable change in ﬂuorescence
was observed upon incubation with the A box protein. A fusion
protein containing the GST-acidic tail of HMGB1 showed no
change in ﬂuorescence, conﬁrming that the HMGB1 acidic tail
plays no role in LPS catalysis [14].
We further investigated the binding of HMGB1 A and B box
proteins to CD14. When GST-HMGB1 was incubated with whole-
cell lysates of RAW264.7 cells as a CD14 protein source (Fig. 4B,
top) or puriﬁed recombinant CD14 protein (Fig. 4B, middle) and
then precipitated with glutathione–agarose beads, binding of
CD14 was clearly observed, as expected. HMGB1 interacted with
CD14 via the HMGB1 B box domain (Fig. 4B, bottom). Next, we
investigated whether HPep1 and HPep6 could facilitate the
ﬂuorescence transition from an aggregated BODIPY FL-LPS state.
However, treatment with HPep1 and/or HPep6 did not facilitate
LPS transfer to CD14, although both these peptides bound to LPS
(Fig. 4C), suggesting that the CD14-binding region is different
from the LPS-binding regions of HMGB1.
HPep1 and HPep6 inhibit LBP-mediated LPS transfer to
CD14
Both HPep1 and HPep6 inhibited LPS binding to LBP and HMGB1
(Fig. 3B and C), and we next tested whether the next step of LPS
transfer to CD14 molecule could be inhibited by these peptides.
HPep1 and HPep6 were incubated with a constant amount of
BODIPY FL-LPS and LBP in the presence or absence of sCD14.
Both HPep1 and HPep6 inhibited the LBP-mediated transfer of
BODIPY FL-LPS to sCD14 in a dose-dependent manner (Fig. 5A).
Next, we investigated whether HPep1 and HPep6 could also
inhibit LBP-mediated LPS transfer at the cellular level. RAW264.7
cells were incubated at 371C for 60min with a preincubated
mixture of BODIPY FL-LPS and LBP in the presence or absence of
50mg/mL of each HMGB1 peptide, and the ﬂuorescence
produced by RAW264.7 cells was measured after washing. As
shown in Fig. 5B, HPep1 and HPep6 signiﬁcantly inhibited LBP-
mediated LPS transfer to RAW264.7 cells.
We further analyzed whether HPep1 and HPep6 could inhibit
the direct binding of LPS to RAW264.7 cells using ﬂow cytometry.
RAW264.7 cells were incubated with a preincubated mixture of
Figure 3. Binding of HMGB1 peptides to LPS. (A) Competitive binding analysis of the interaction between the HMGB1 peptides and LPS. Microtiter
plates were coated with LPS, and the same amount of peptide No. 1 (HPep1) or No. 6 (HPep6) was added to the wells in the presence of various
amounts of S. minnesota Re595 LPS, S. minnetosa lipid A, or E. coli delipidated LPS. WT S. minnetosa LPS was used as a positive control inhibitor. The
binding of the HMGB1 peptides to LPS was probed by HRP-conjugated streptavidin. (B, C) Inhibition of LPS binding to LBP and HMGB1 by HMGB1
peptides. (B) Brieﬂy, 100ng/mL of LBP was added to LPS-coated wells in the presence of various amounts of HMGB1 peptides. The binding of LBP to
LPS was probed using an anti-LBP Ab. Polymyxin B was used as a positive control inhibitor. (C) Biotin-labeled LPS was incubated with 5mg/mL of
HMGB1 in the presence of a mixture of HPep1 and HPep6 peptides, and pull-down assays were performed using streptavidin agarose beads.
Western blot analysis was performed using anti-HMGB1 Ab. Data shown are representative of two independent experiments.
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with the same concentrations of HPep1 and HPep6, the mean
ﬂuorescence intensity (MFI) of FITC-LPS to RAW264.7 cells
decreased from 69.8 (FITC-LPS only) to 12.0 and 8.4, respec-
tively (Fig. 5C). These data indicate that HPep1 and HPep6
inhibit binding of LPS to RAW264.7 cells.
HPep1 and HPep6 inhibit LPS-induced TNF-a produc-
tion in human PBMCs
We next measured whether HPep1 and HPep6 had a neutralizing
effect on LPS-induced TNF-a production in human PBMCs.
Human PBMCs were treated with 1ng/mL of LPS in the presence
of 200ng/mL of LBP and 2.5mg/mL of each HMGB1 peptide for
16h, and TNF-a in the culture supernatants was measured. When
human PBMCs were treated with LPS in the absence of HMGB1
peptide, the mean level of TNF-a production was 500pg/mL.
TNF-a production decreased to 124 and 71pg/mL after the
addition of HPep1 or HPep6 respectively. Approximately 111pg/
mL of TNF-a was produced when human PBMCs were treated
with 1ng/mL of LPS without the addition of LBP. Other HMGB1
peptides did not inhibit LPS-induced TNF-a production. These
data suggest that HPep1 and HPep6 function as LPS-neutralizing
peptides (Fig. 6).
HPep1 and HPep6 inhibit LPS-induced TNF-a produc-
tion in a subclinical endotoxemia mouse model
Finally, we tested whether HPep1 and HPep6 can inhibit LPS-
induced TNF-a production in vivo using a mouse model. BALB/c
Figure 4. Ability of HMGB1 A- and B-box domain-containing peptides to transfer BODIPY FL-LPS to CD14. (A) A mixture of BODIPY FL-LPS and
sCD14 was incubated in the presence of HMGB1 A box, B box, and GST-acidic tail proteins, and ﬂuorescence levels were measured after 10h at
251C. LBP was used as a positive control, and 2% SDS was used to completely solubilize the disaggregated state of LPS for maximum ﬂuorescence.
(B) Interaction of HMGB1 with CD14. Either 2 or 10mg of GST-HMGB1 protein was incubated with whole cell lysate from RAW264.7 cells (top) or
recombinant CD14 protein (middle) and then precipitated with glutathione-Sepharose 4B beads. Western blot analysis was performed using an
anti-CD14 Ab. Whole-cell lysate was loaded as a positive control. Binding of HMGB1 A and B box peptides to recombinant CD14 protein was
measured by ELISA (bottom). A titration of 6-His-tagged A and B box proteins were added to the CD14-coated wells and anti-His Ab was used as the
primary Ab. (C) HMGB1 peptide-mediated transfer of LPS to sCD14. In all, 1mg/mL of BODIPY FL-LPS and 5mg/mL of CD14 protein were incubated in
the presence of 2.5mg/mL of each HMGB1 peptide. Fluorescence levels were measured at 525nm with a 488nm excitation after 10h at 251C. LBP and
HMGB1 proteins were used as positive controls. Heat-treated (Hx) HMGB1 was used as a control. Data shown are representative of three
independent experiments. Error bars: standard deviation.
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100ng of LPS in the presence or absence of 100mg of HPep1 or
HPep6, and serum samples were collected 2h after LPS injection.
HMGB1 peptide No. 3 (HPep3) was used as a negative control
peptide. As shown in Fig. 7, the mean serum TNF-a level in the
LPS-treated group was 903pg/mL. However, in mice injected
with LPS in combination with HPep1 or HPep6, serum TNF-a
levels were reduced to 120 and 123pg/mL respectively. The level
Figure 5. Inhibition of LPS transfer by HPep1 and HPep6. (A) A mixture of BODIPY FL-LPS, CD14 protein, and LBP was incubated in the presence of
various amounts of HPep1 and HPep6, and changes in ﬂuorescence levels were measured. (B) RAW264.7 cells were incubated with a mixture of
BODIPY FL-LPS and LBP in the presence of each HMGB1 peptide and the ﬂuorescence levels of RAW264.7 cells were measured after washing.
(C) RAW264.7 cells were incubated with a preincubated mixture of 100mg/mL of FITC-conjugated LPS and 100mg/mL of HMGB1 peptide HPep1 or
HPep6 in 10% FBS-DMEM. The binding of FITC-LPS was analyzed by ﬂow cytometry after washing. Data shown are representative of two or three
independent experiments.
Figure 6. Inhibition of TNF-a production in human PBMCs by HMGB1 peptides. Human PBMCs (510
6cells/mL) were stimulated with a
preincubated mixture of 1ng/mL of LPS and 200ng/mL of LBP in the presence of 2.5mg/mL of each HMGB1 peptide in serum-free Opti-MEM
s
medium. The cultures were incubated 16h at 371C and the concentration of TNF-a in the culture supernatants was determined using sandwich
ELISA. Data shown are mean and standard deviation of three independent experiments.
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from that in the LPS-injected group.
Discussion
In a previous study, we demonstrated that HMGB1 is an LPS-
binding molecule that can transfer LPS to CD14 and eventually to
TLR4-MD2 receptors, thereby resulting in TNF-a production [14].
In the current study, we demonstrated that HMGB1 has two LPS-
binding motifs located in its A and B box domains respectively,
and that two synthetic peptides (HPep1 and HPep6) containing
each of these LPS-binding motifs respectively, can inhibit LPS-
stimulated TNF-a production both ex vivo in human PBMCs and
in vivo in a mouse model of subclinical endotoxemia. Peptides
derived from several LBPs, namely LBP, bactericidal/permeabil-
ity-increasing protein, limulus anti-LPS factor [21], serum
amyloid protein [22, 23], lactoferrin [24], cationic protein
(CAP)18 [25], and CAP37 [26] antagonize LPS (review
[27, 28]). To this list, we can now add the two novel HMGB1-
derived peptides HPep1 and HPep6.
Lipid A is the main target of LPS-neutralizing peptides [29].
Lipid A-binding peptides contain basic residues that interact
ionically with the phosphate head groups of lipid A [27]. LPS-
binding peptides have the motif of BBXB (B: any basic aa, X: any
hydrophobic aa) [30, 31], which is a known binding site for both
LPS and heparin. Another LPS-binding motif is a tripeptide of
BZB residues (B: any basic aa, Z: aromatic ring-containing aa);
the aromatic residue in this position plays an important role in
LPS binding as revealed by a mutation study [32]. The HMGB1-
derived peptide HPep6 (PPKGETKKKFKDPNAPK), which binds to
lipid A, has overlapping BBXB and BZB motifs, whereas HPep1
(KGDPKKPRGKMSS), which binds to the polysaccharide portion
of LPS, has a BBXB motif. However, a peptide sequence analysis
of 29 LPS- or lipid A-binding dodecapeptides, selected by
biopanning phage peptide library assay, revealed that these
peptides are remarkably diverse sequences and have a high
average pI value of 11.42 [33]. All dodecapeptides had predicted
helical contents ranged from 0.0 to 0.26 based on the predictions
of helix content by Agadir algorithm (http://agadir.crg.es)
[34, 35]. These peptides had remarkably diverse sequences and
structural propensities not limited to an amphipathic a-helical
structure although many natural linear short peptides adopt an
a-helical structure, suggesting that the potential of an amphi-
pathic structure of short peptides may not be the prerequisite of
LPS-binding afﬁnity [33]. The HPep1 and Hpep6 peptides have
relatively high pI values of 10.46 and 10.01 respectively, but
show very different aa sequences and predicted helical contents
of 0.01 and 0.23 by Agadir algorithm respectively, suggesting
different helical structures.
HPep1 inhibited LPS binding to LBP and LPS-mediated TNF-a
production in human PBMCs and mice with subclinical endotox-
emia, although it is not a lipid A-binding peptide. Deacylated LPS
can antagonize LPS at multiple LPS–LBP-binding sites in the LPS
recognition pathway [36, 37], suggesting that the polysaccharide
moiety of LPS plays an important role in LPS recognition. HPep1
binding to the polysaccharide moiety of LPS showed a similar
inhibition mechanism as that of deacylated LPS. This, to the best of
our knowledge, is the ﬁrst study to report that a polysaccharide
moiety-binding peptide can neutralize the binding of LPS to LBP.
Further investigation is required to elucidate how binding of
HPep1 to the polysaccharide moiety of LPS can inhibit the
LPS–LBP interaction. CD14 binding is necessary for LBP-mediated
LPS transfer [38], and LBP has both an LPS-binding domain and
an LPS-transfer domain [39]. The HMGB1 B box protein has both a
lipid A-binding motif and can bind to CD14, allowing the transfer
of BODIPY FL-LPS to CD14. On the contrary, the HMGB1 A box
protein has a polysaccharide-binding motif and shows little or no
binding to CD14, and can therefore not affect LPS transfer. These
results indicate that the HMGB1 B box domain plays a major role
in HMGB1-mediated LPS transfer and LPS-mediated proin-
ﬂammatory function. We are now studying the CD14-binding
region of the HMGB1 B box domain.
LPS-neutralizing peptides are attractive for potential ther-
apeutic use. Treatment of mice with either HPep1 or HPep6
resulted in reduced LPS-induced TNF-a production and both
peptides showed no hemolytic activity (data not shown). HPep1
and HPep6 inhibited binding of LPS to LBP and HMGB1 by
binding to different target sites on LPS, and further evaluation is
necessary to determine whether combined treatment with both
peptides can inhibit LPS-mediated TNF-a production to a greater
extent than treatment with each peptide alone. One of the main
problems associated with peptide therapy is the short half-life of
peptides in serum caused by proteolytic degradation, and there-
fore optimization of peptide stability for longer persistence in
blood, for example a tetrabranched peptide, may be necessary
[40]. The stability of HPep1 and HPep6 peptides in serum and
their possible use as anti-microbial peptides need to be evaluated
in the future studies.
Figure 7. Neutralizing effect of the HMGB1 peptides HPep1 and HPep6
in a subclinical endotoxemia mouse model. BALB/c mice were injected
intravenously with a subclinical dose of 100ng of ultrapure E. coli LPS
and 100mg of HPep1 or HPep6. HPep3 (HMGB1 peptide No. 3), which
does not bind to LPS, was used as a negative control. Six mice per group
were evaluated. Serum samples were collected 2h after injection and
the serum concentration of TNF-a was determined using sandwich
ELISA. Error bars of standard deviation are represented. Data shown
are representative of two independent experiments. Dunn’s test
(nonparametric) was used for calculation of the p-values.
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polysaccharide-binding motifs that can neutralize LPS-mediated
TNF-a release in human PBMCs and in a subclinical endotoxemia
mouse model; peptides that cover these binding regions may
potentially be used as anti-septic therapeutic agents and contri-
bute the survival rate for pathological condition of LPS-mediated
sepsis.
Materials and methods
LPS, synthetic peptides, and recombinant proteins
WT LPS (E. coli 0111:B4), Remutant LPS (lipid A and the sole
constituent of the core of 2-keto-3-deoxyoctonate from Salmo-
nella minnesota Re595), delipidated LPS (E. coli 0111:B4), lipid A
(S. minnesota), and biotin-labeled E. coli LPS were purchased
from Sigma. Delipidated LPS is partially delipidated product by
alkaline hydrolysis. Recombinant human LBP and soluble CD14
protein (sCD14, aa 1-352) were purchased from R&D. Recombi-
nant human HMGB1, HMGB1 A (aa 1-17), and B (aa 88-162) box
proteins were produced previously [5]. GST-HMGB1 and GST-
acidic tail of HMGB1 (aa 186-215) constructs were subcloned
and expressed in E. coli BL21. To map the LPS-binding region of
HMGB1, 12 biotin-labeled HMGB1 peptides (HPep1–HPep12)
were synthesized (Peptron, South Korea) (Fig. 2A). Biotin-free
synthetic peptides of HMGB1 were used for biological assays of
TNF-a production.
ELISA and competition ELISA
LPS ELISAs were performed as described previously [14].
Microtiter plates (Corning) were coated with 1–10mg/mL of LPS
from S. minnesota, and blocked with 3% BSA-PBST. Each biotin-
labeled HMGB1 peptide was added to the wells and incubated for
2h at room temperature. HRP-conjugated streptavidin (R&D) was
incubated for an additional 1.5h. TMB solution was used for color
development. To investigate the binding of HMGB1 A and B box
domains to sCD14, various amounts of HMGB1 A and B box
proteins were added to the wells coated with 10mg/mL of sCD14
for 3h at room temperature. Anti-His Ab was used as a primary Ab.
A competitive ELISA was performed to investigate the binding
speciﬁcity of HMGB1 to LPS. A constant amount of biotin-labeled
HMGB1 peptide was incubated in LPS-coated wells in the
presence of various concentrations of lipid A, Re595, delipidated
LPS, or WT LPS as inhibitors. WT LPS was used as a positive
control inhibitor. The binding of HMGB1 peptide was probed by
HRP-conjugated streptavidin. To investigate whether the HMGB1
peptides could inhibit the binding of LBP to LPS, 100ng/mL of
LBP was added to LPS-coated wells (5mg/mL) in the presence of
various amounts of HMGB1 peptides. The binding of LBP to LPS
was probed using a polyclonal anti-LBP Ab (Abcam). Polymyxin B
(USB) was used as a positive control inhibitor.
Pull-down assays and Western blotting analysis
To analyze the binding of HMGB1 A and B box proteins to LPS,
10mg/mL of biotin-labeled LPS (E. coli, Molecular Probes)
was incubated with 10mg/mL of HMGB1 A and B box
proteins and a pull-down assay was performed using 50mg/mL
(50% slurry) streptavidin agarose beads (Pierce). The beads
were washed and subjected to 12% SDS-PAGE followed by the
transfer of proteins to a nitrocellulose membrane. Western blot
analysis was performed using an anti-His Ab (Qiagen) and HRP-
labeled goat anti-rabbit Ig as primary and secondary Abs,
respectively.
To investigate which moieties of LPS the A and B box
domains of HMGB1 recognize and bind to, a competition assay
was performed. An aliquot of 5mg/mL of biotin–LPS was
incubated for 6h with 5mg/mL of His-tagged A box or B box
HMGB1 protein that had been preincubated with various
amounts of inhibitors (delipidated LPS, lipid A, Re595 LPS, or WT
LPS) for 1h at 41C. Biotin–LPS was precipitated using streptavi-
din agarose beads and analyzed using a Western blot assay with
anti-His Ab.
To investigate the binding of HMGB1 to LPS, 10mg/mL of
each biotin-labeled HMGB1 peptide was incubated with 10mg/
mL of LPS (E. coli and S. enterica serotype typhimurium) for 4h.
His-tagged HMGB1 protein (30mg/mL) was used as a positive
control. The pull-down complexes using streptavidin agarose
beads were separated by 12% SDS-PAGE and analyzed by
Western blotting with anti-LPS Ab (Hycult Biotech). To identify
HMGB1 binding to CD14, RAW264.7 cells were lysed with a
protease inhibitor cocktail. Cell homogenates were centrifuged at
20000g for 15min and precleared by incubating with gluta-
thione-Sepharose 4B beads at 41C for 30min. The precleared
extracts (500mg) were incubated with 2mg/mL of GST-HMGB1 or
GST immobilized on glutathione-Sepharose 4B beads for
Western blotting. The membrane was blotted with anti-CD14 Ab
(R&D).
Measurement of BODIPY FL-LPS transfer to CD14 by
ﬂuorescence
LPS transfer to sCD14 was measured using the disaggregation
method of BODIPY FL-LPS [14]. Brieﬂy, 1mg/mL of BODIPY
FL-LPS (Molecular Probes) and 5mg/mL of sCD14 protein
were added to Ca
11 and Mg
11-free PBS in the presence of
recombinant HMGB1 A or B box protein or each HMGB1 peptide.
Human LBP protein was used as a positive control. The
ﬂuorescence levels were measured at 525nm at an excitation
wavelength of 488nm after 10h at 251C. Complete disaggrega-
tion of BODIPY FL-LPS by 2% SDS was measured. To investigate
LPS transfer at the cellular level, 110
6 RAW264.7 cells were
incubated in 10% FBS-containing medium with BODIPY FL-LPS
in the presence of each peptide for 60min at 371C. The cell-
associated ﬂuorescence was measured after washing by a
spectroﬂuorometer.
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FITC-conjugated LPS (100mg/mL, Sigma) was preincubated for
30min at 251C with each HMGB1 peptide at a concentration of
100mg/mL in 10% FBS-DMEM. The mixture was then added to
510
5 RAW264.7 cells and further incubated for 30min at 251C.
The cells were washed three times with cold PBS and ﬁxed in 1%
paraformaldehyde solution. The binding of FITC-LPS was
analyzed by LSRII ﬂow cytometry (BD). The mean ﬂuorescence
intensity (MFI) was measured.
TNF-a production
Human PBMCs were isolated from the blood of normal subjects
by Ficoll-hypaque gradient centrifugation after obtaining the
permission of the IRB (4-2007-0059), and cultured in serum-free
Opti-MEM
s medium (Invitrogen) at 510
6cells/mL in 96-well
plates [14]. PBMCs were treated with a mixture of 1ng/mL of
LPS and 2.5mg/mL of each HMGB1 peptide; the peptides were
preincubated for 30min at 371C with 200ng/mL of LBP. The
cultures were incubated for 16h at 371C and the culture
supernatants were collected after centrifugation. The concentra-
tion of TNF-a was determined using a sandwich ELISA assay
(R&D).
Induction of subclinical endotoxemia in a mouse
model
To evaluate whether 2 of the 12 HMGB1 peptides had a
neutralizing effect, BALB/c mice (6–8wk) were intravenously
injected with a subclinical dose of 100ng of LPS (Ultrapure E. coli
LPS, Invitrogen) in the presence of 100mg of HMGB1 HPep1 or
HPep6 after obtaining the permission of the animal IRB of our
institution (approval No. 08-151). HPep3, which does not bind to
LPS, was used as the negative control peptide. Serum samples
were collected 2h after injection. The levels of TNF-a in mouse
serum samples were determined using a sandwich ELISA (R&D)
after diluting the serum samples 1:10.
Statistical analysis
Dunn’s test (nonparametric) was implemented in SAS 9.1 to
analyze the data of subclinical endotoxemia in a mouse model.
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